Lantheus Holdings stock (US5156731020): Q1 earnings beat sparks 44% YTD rally

Lantheus Holdings reported Q1 2026 EPS of $1.46, topping estimates by 21%, with revenue at $377.3 million up 1.2% YoY. Shares hit new 52-week highs near $96 amid radiopharma momentum.

Lantheus Holdings stock surged after the company released stronger-than-expected Q1 2026 earnings on May 7, 2026. The medical imaging specialist posted EPS of $1.46, beating the $1.25 consensus by $0.21, while revenue climbed 1.2% to $377.3 million, according to the MarketBeat summary as of May 2026 and Investing.com transcript as of May 2026. Since the earnings, shares have rallied, trading at $96.23 on Nasdaq with a 44.6% YTD gain and recent 52-week highs.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lantheus Holdings, Inc.
• Sector/industry: Medical / Diagnostic Imaging & Radiopharmaceuticals
• Headquarters/country: North Billerica, Massachusetts, USA
• Core markets: Cardiovascular and oncology diagnostics
• Key revenue drivers: PYLARIFY, TechneLite
• Home exchange/listing venue: Nasdaq (LNTH)
• Trading currency: USD

Lantheus Holdings: core business model

Lantheus Holdings develops, manufactures, and commercializes diagnostic imaging agents and radiopharmaceuticals for cardiovascular and oncologic diseases. Headquartered in Massachusetts, the company serves global markets with products like PYLARIFY, a PSMA-targeted PET agent for prostate cancer detection, which has driven significant revenue growth. Its portfolio includes TechneLite for nuclear medicine applications, positioning Lantheus as a key player in precision diagnostics relevant to US healthcare investors via Nasdaq listing.

The business model emphasizes innovation in radiopharma, with manufacturing facilities supporting high-demand imaging agents. Lantheus reported net income of $233.56 million over the trailing 12 months as of May 2026, per MarketBeat as of May 2026, reflecting strong margins of 18.05%.

Main revenue and product drivers for Lantheus Holdings

PYLARIFY remains the top revenue driver, benefiting from expanded prostate cancer screening in the US. Q1 2026 revenue of $377.3 million underscores steady demand, up 1.2% YoY despite market headwinds. Other contributors include cardiovascular agents, supporting Lantheus' 15% return on assets for the period ending Q1 2026 per company filings summarized on MarketBeat.

Fluorine-18 based agents, highlighted in industry reports, bolster Lantheus' position in nuclear medicine, with production scaling to meet US hospital needs. The stock's P/E ratio of 23.52 as of May 2026 reflects investor confidence in these drivers.

Industry trends and competitive position

The radiopharmaceutical sector is expanding with rising cancer incidence and advanced imaging adoption in the US. Lantheus competes with peers in PSMA-PET but leads via PYLARIFY's FDA approval and distribution network. Market cap stands at $6.24 billion, with shares up 44.6% YTD to $96.23 on Nasdaq as of May 2026 per MarketBeat.

Why Lantheus Holdings matters for US investors

Lantheus' Nasdaq listing (LNTH) and focus on US-centric diagnostics like prostate imaging tie it to American healthcare spending trends. With 1,193 employees and exposure to Medicare-reimbursed procedures, it offers retail investors a play on precision medicine growth amid aging demographics.

Conclusion

Lantheus Holdings' Q1 2026 earnings beat highlights resilient demand for its radiopharma products amid a strong YTD stock performance. With robust margins and a leading position in diagnostic imaging, the company continues to deliver value in a growing sector. Investors track upcoming catalysts like pipeline expansions for sustained momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.